We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Consortium to Develop Artificial Retina

By Biotechdaily staff writers
Posted on 08 Nov 2004
A consortium has recently agreed to jointly develop technology that could restore sight to those who have lost their sight later in life.

A U.S. More...
Department of Energy (DOE) consortium of national laboratories, including Lawrence Livermore National Laboratory (LLNL, Livermore, CA, USA) and several universities, have signed an agreement with Second Sight Medical Products, Inc. (Sylmar, CA, USA) to form a Cooperative Research and Development Agreement (CRADA), which allows Second Sight Medical Products to obtain a limited exclusive license for inventions developed during the DOE Retinal Prosthesis Project.

An artificial retina could restore vision to millions of people with eye disorders ranging from macular degeneration to retinitis pigmentosa, or those who are legally blind due to the loss of photoreceptor function. Scientists from LLNL's Center for Micro- and Nanotechnology are specifically developing a flexible silicone implant (microelectrode array) that sits on the surface of the retina. The electrode array can contact fragile retinal tissue without damaging it. The implantable retinal prosthesis is based on a system that transforms a video camera signal into a stimulation pattern that is applied directly to the interlobular retinal surface. This is known as an epiretinal implant--the device is in contact with the retina's surface. Visual signals are acquired by a small video camera in the eyeglasses of the blind individual and processed through a microcomputer worn on a belt.

Even though the device will not restore full vision, it will probably provide enough optical resolution for patient to read and recognize fine shapes. LLNL's innovative use of polydimethlsiloxane (PDMS) allowed the microelectrode array to conform to the curved shape of the retina.

"PDMS has the look and feel of thin plastic food wrap, yet it's biocompatible, making it a good candidate material for long-term implant,” Courtney Davidson, Livermore's main investigator.



Related Links:
Lawrence Livermore National Laboratory
Second Sight Medical Products

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.